Eisai Appoints Global Clinical Quality Assurance VP

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has appointed Priya Chaturvedi, Ph.D., as vice president, Global Clinical Quality Assurance. Dr. Chaturvedi will be responsible for developing, implementing and monitoring global policies and procedures to assure worldwide compliance with good clinical practices (GCP) and the laws and regulations governing drug development.

Prior to joining Eisai, Dr. Chaturvedi served as executive director, Clinical Quality Assurance, head of Global GCP for Infectious Disease and Vaccines at Merck Research Labs, where she oversaw the end-to-end quality assurance for a large portfolio of clinical trials across all therapeutic areas in the Asia-Pacific region, including China. Prior to Merck, she held various roles at Pfizer within the Quality function, and at GlaxoSmithKline in drug discovery aimed at the identification of predictive biomarkers and novel drug targets.
 

"Priya is an experienced quality leader who brings a wealth of expertise in clinical quality assurance and GCP compliance to Eisai. She has an extensive background leading teams in conducting audits, supporting inspections and issue management," said Dr. Hiroyuki Kato, senior vice president, Eisai's chief clinical quality officer. "We are excited to have Priya join our leadership team as we enhance our Quality organization to align with Eisai's goal of Breaking Through to address some of society's most difficult health care challenges."

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content, 

please email: Julia.Zhang@ubmsinoexpo.com to delete.